Drug Profile
Plinabulin - BeyondSpring Pharmaceuticals
Alternative Names: BPI 2358; NPI 2358Latest Information Update: 07 Nov 2023
Price :
$50
*
At a glance
- Originator Nereus Pharmaceuticals
- Developer BeyondSpring Pharmaceuticals; Big Ten Cancer Research Consortium; M. D. Anderson Cancer Center; Nereus Pharmaceuticals; Rutgers Cancer Institute of New Jersey
- Class Antineoplastics; Imidazoles; Piperazines; Small molecules
- Mechanism of Action Antigen presenting cell stimulants; Guanine nucleotide exchange factor stimulants; Tubulin modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preregistration Neutropenia
- Phase III Non-small cell lung cancer
- Phase I/II Cancer; Small cell lung cancer
- Preclinical Bladder cancer; Breast cancer; Gastric cancer; Glioblastoma; Sickle cell anaemia; Soft tissue sarcoma
- No development reported Brain cancer; Solid tumours
Most Recent Events
- 01 Nov 2023 Pharmacodynamics data from a preclinical trial in Glioblastoma released by the BeyondSpring Pharmaceuticals
- 07 Jun 2023 Efficacy and adverse events data from phase-II trial in Neutropenia released by BeyondSpring
- 02 Jun 2023 Efficacy and adverse events data from phase I trial in Multiple myeloma presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)